Please try another search
Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.
Name | Age | Since | Title |
---|---|---|---|
Jonathan Kenneth Charles Knowles | 75 | 2015 | Chairman of the Scientific Advisory Board |
John Poulos | 70 | 2017 | Independent Non-Executive Director |
Markku Tapani Jalkanen | 70 | 2006 | Founder, CEO & Executive Director |
Huaizheng Peng | 62 | 2015 | Board Observer |
Christophe Massard | - | 2019 | Member of the Scientific Advisory Board |
David Adams | - | 2019 | Member of the Scientific Advisory Board |
Marie-Louise Helena Fjallskog | 60 | 2022 | Independent Non-Executive Director |
Christine Ann Roth | 61 | 2023 | Independent Non-Executive Director |
Sirpa Jalkanen | 70 | 2019 | Member of the Scientific Advisory Board |
Tyler Curiel | - | 2021 | Member of the Scientific Advisory Board |
Tuomo Patsi | 60 | 2023 | Independent Non-Executive Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review